Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes

Journal of Virology

Volumn 72, Issue 11, 1998, Pages 8644-8649

  Pepperl, Sandra ^a   Benninger döring, Gerlinde ^a   Modrow, Susanne ^a   Wolf, Hans ^a   Jilg, Wolfgang ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A ANTIGEN; RTA PROTEIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMEDIATE EARLY GENE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; TRANSACTIVATION; VACCINIA VIRUS; VIRUS GENE; VIRUS RECOMBINANT;

EID: 0031657975     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.11.8644-8649.1998     Document Type: Article

References (49)

1. Barnstable, C. J., W. Bodmer, G. Brown, G. Galfre, C. Milstein, A. F. Williams, and A. Ziegler. 1978. Production of monoclonal antibodies group A erythrocytes, HLA and other human cell surface antigens - a new tool for genetic analysis. Cell 14:9-20.
2. Blake, N. W., S. Kettle, K. M. Law, K. Gould, J. Bastin, R. M. Townsend and G. L. Smith. 1995. Vaccinia virus serpins B13R and B22R do not inhibit antigen presentation to class I restricted cytotoxic T lymphocytes. J. Gen. Virol. 76:2393-2398.
3. Bogedain, C., P. Alliger, F. Schwarzmann, M. Marshall, H. Wolf, and W. Jilg. 1994. Different activation of Epstein-Barr virus immediate-early and early genes in Burkitt's lymphoma cells and lymphoblastoid cell lines. J. Virol. 68:1200-1203.
4. Bogedain, C., H. Wolf, S. Modrow, G. Stuber, and W. Jilg. 1995. Specific cytotoxic T cells recognize the immediate-early transactivator Zta of Epstein-Barr virus. J. Virol. 69:4872-4879.
5. Brooks, J. M., R. J. Murray, W. A. Thomas, M. G. Kurilla, and A. B. Rickinson. 1993. Different HLA B27 subtypes present the same immunodominant EBV-peptide. J. Exp. Med. 178:879-887.
6. Burrows, S. R., I. S. Misko, T. B. Sculley, C. Schmidt, and D. J. Moss. 1990. An Epstein-Barr virus-specific cytotoxic T-cell epitope present on A- and H-type transformants. J. Virol. 64:3974-3976.
7. Burrows, S. R., T. B. Sculley, I. S. Misko, C. Schmidt, and D. J. Moss. 1990. An EBV-specific cytotoxic T cell epitope in EBNA 3. J. Exp. Med. 171:345-149.
8. Burrows, S. R., S. Rodda, A. Suhrbier, H. M. Geysen, and D. J. Moss. 1992. The specificity of recognition of a cytotoxic T lymphocyte epitope. Eur. J. Immunol. 22:191-195.
9. Burrows, S. R., J. Gardner, R. Khanna, T. Steward, D. J. Moss, S. Rodda, and A. Suhrbier. 1994. Five new CTL epitopes identified within EBNA 3A. J. Gen. Virol. 75:2489-2493.
10. Colonna, M., G. Borselino, G. B. Falco, B. Ferrara, and J. L. Strominger. 1993. HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells. Proc. Natl. Acad. Sci. USA 90:12000-12004.
11. DeCampos-Lima, P. O., R. Gavioli, Q. J. Zhang, L. Wallace, R. Dolcetti, M. Rowe, A. B. Rickinson, and M. G. Masucci. 1993. HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11 positive population. Science 260:98-100.
12. Dupont, B. 1989. Immunobiology of HLA, vol. 1. Histocompatibility testing. Springer Verlag, New York, N.Y.
13. Ernberg, I., and E. Altiok, 1989. The role of Epstein-Barr virus in lymphomas of HIV carriers. APMIS Suppl. 8:58-61.
14. Falk, K., O. Rötzschke, S. Stevanovic, G. Jung, and H. G. Rammensee. 1991. Allele-specific motifs revealed by sequencing of self peptides eluted from MHC-molecules. Nature 351:290-296.
15. Falk, K., O. Rötzschke, B. Grahovac, D. Schendel, S. Stevanovic, V. Gnau, G. Jung, and H. G. Rammensee. 1993. Allele-specific peptide ligand motifs of HLA-C molecules. Proc. Natl. Acad. Sci. USA 90:12005-12009.
16. Gavioli, R., M. G. Kurilla, P. O. DeCampos-Lima, L. E. Wallace, R. Dolcetti, R. J. Murray, A. B. Rickinson, and M. G. Masucci. 1993. Multiple HLA-A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the EBNA-4 protein. J. Virol. 67:1572-1578.
17. Gratama, J. W., M. A. Osterveer, F. E. Zwaan, J. Lepoutre, G. Klein, and I. Ernberg. 1988. Eradication of Epstein-Barr virus by allogenic bone marrow transplant recipients: implications for sites of viral latency. Proc. Natl. Acad. Sci. USA 85:8693-8696.
18. Hill, A., S. P. Lee, J. S. Haurum, N. Murray, Q. Yao, M. Rowe, N. Signoret, A. B. Rickinson, and M. G. Masucci. 1995. Class I MHC-restricted CTL's specific for EBV nuclear antigens fail to lyse the EBV-transformed LCL's against which they were raised. J. Exp. Med. 181:2221-2228.
19. Hill, A., A. Worth, T. Elliot, S. Rowland Jones, J. Brooks, A. B. Rickinson, and M. G. Masucci. 1995. Characterization of two EBV epitopes restricted by HLA-B7. Eur. J. Immunol. 25:18-24.
20. Imanishi, T., T. Akaza, A. Kimura, K. Tokunaga, and T. Gojobori. 1992. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups, p. 1065-1074. In K. Tsuji, M. Aizawa, and T. Sazazuki (ed.), HLA 1991. Proceedings of the 11th International Histocompatibility Workshop and Conference, vol. 1. Oxford University Press, Oxford, England.
21. Kerr, B. M., N. Kienzle, J. M. Burrows, S. Cross, S. L. Silins, M. Buck, E. M. Benson, B. Coupar, D. J. Moss, and T. B. Sculley. 1996. Identification of type B-specific and cross-reactive cytotoxic T-lymphocyte responses to Epstein-Barr virus. J. Virol. 70:8858-8864.
22. Khanna, R., S. R. Burrows, M. G. Kurilla, C. A. Jacob, I. S. Misko, T. Sculley, E. Kieff, and D. J. Moss. 1992. Localization of EBV cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J. Exp. Med. 176:169-176.
23. Khanna, R., S. R. Burrows, and D. J. Moss. 1995. Immune regulation in Epstein-Barr virus-associated diseases. Microbiol. Rev. 59:387-405.
24. Khyatti, M., P. C. Patel, I. Stefanescu, and J. Menezes. 1991. Epstein-Barr virus glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target for Epstein-Barr virus-specific antibody-dependent cellular cytotoxicity. J. Virol. 72:1622-1626.
25. Klein, G. 1994. Epstein-Barr virus strategy in normal and neoplastic B cells. Cell 77:791-793.
26. Lee, S. P., W. A. Thomas, R. J. Murray, F. Khanim, S. Kaur, L. S. Young, M. Rowe, M. Kurilla, and A. B. Rickinson. 1993. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J. Virol. 67:7428-7435.
27. Lee, S. P., R. J. Tierney, W. A. Thomas, J. M. Brooks, and A. B. Rickinson. 1997. Conserved CTL epitopes within EBV latent membrane protein 2. J. Immunol. 158:3325-3334.
28. Levitskaya, J., M. Coram, V. Levitsky, S. Imreh, P. M. Steigerwald-Mullen, G. Klein, M. G. Kurilla, and M. G. Masucci. 1995. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375:685-688.
29. Maier, R., K. Falk, O. Rötzschke, B. Maier, V. Gnau, S. Stevanovic, G. Jung, H. G. Rammensee, and A. Meyerhans. 1994. Peptide motifs of HLA-A3, -A24, and -B7 molecules as determined by pool sequencing. Immunogenetics 40:306-308.
30. McCutcheon, J. A., J. Gumperz, K. D. Smith, C. T. Lutz, and P. Parham. 1995. Low HLA-C expression at cell surfaces correlates with increased turnover of heavy chain mRNA. J. Exp. Med. 181:2085-2095.
31. Modrow, S., B. Höflacher, and K, Mellert. 1989. Use of synthetic oligopeptides in identification and characterization of immunological functions in the amino acid sequence of the envelope protein of HIV-1. J. Acquired Immune Defic. Syndr. 2:21-27.
32. Morgan, S. M., G. W. Wilkinson, E. Floettmann, N. Blake, and A. B. Rickinson. 1996. A recombinant adenovirus expressing an Epstein-Barr virus (EBV) target antigen can selectively reactivate rare components of EBV cytotoxic T-lymphocyte memory in vitro. J. Virol. 70:2394-2402.
33. Moss, D. J., S. R. Burrows, R. Khanna, I. S. Misko, and T. B. Sculley. 1992. Immune surveillance against Epstein-Barr virus. Semin. Immunol. 4:97-104.
34. Neefjes, J. J., and H. L. Ploegh. 1988. Allele and locus specific differences in cell surface expression and the association of HLA class I heavy chain with B2MG: differential effects of inhibition and glycosylation on class I subunit association. Eur. J. Immunol. 18:801-810.
35. Okano, M., S. Matsumoto, T. Osato, Y. Sakiyama, G. M. Thiele, and D. T. Purtilo. 1991. Severe chronic active Epstein-Barr virus infection syndrome. Clin. Microbiol. Rev. 1:129-135.
36. Pothen, S., J. R. Richert, and G. R. Pearson. 1991. Human T cell recognition of Epstein-Barr virus induced replication antigen complexes. Int. J. Cancer 49:656-660.
37. Prang, N., M. W. Hornef, M. Jäger, H. J. Wagner, H. Wolf, and F. Schwarzmann. 1997. Lytic replication of Epstein-Barr virus in the peripheral blood: analysis of viral gene expression in B lymphocytes during infectious mononucleosis and in the normal carrier state. Blood 89:1665-1677.
38. Rammensee, H.-G., T. Friede, and S. Stevanovic. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41:178-228.
39. Rowe, D. T., L. Qu, J. Reyes, N. Jabbour, E. Yunis, P. Putnam, S. Todo, and M. Green. 1997. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J. Clin. Microbiol. 35:1612-1615.
40. Rowe, M., A. L. Lear, D. Croom-Carter, A. H. Davies, and A. B. Rickinson. 1992. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J. Virol. 66:122-131.
41. Schendel, D. J., P. Reinhardt, P. J. Nelson, B. Maget, L. Pullen, G. W. Bornkamm, and A. Steinle. 1992. Cytotoxic T lymphocytes show HLA-C restricted recognition of EBV bearing cells and allorecognition of HLA class I molecules presenting self peptides. J. Immunol. 149:2406-2414.
42. Steven, N. M., N. E. Annels, A. Kumar, A. M. Leese, M. G. Kurilla, and A. B. Rickinson. 1997. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J. Exp. Med. 185:1605-1617.
43. Strang, G., and A. B. Rickinson. 1987. In vivo expansion of Epstein-Barr virus specific HLA-restricted cytotoxic T cells direct from the blood of infectious mononucleosis patients. Immunology 62:647-654.
44. Thorley-Lawson, D. A., E. M. Miyashita, and G. Khan. 1996. Epstein-Barr virus and the B cell: that's all it takes. Trends Microbiol. 4:204-208.
45. Townsend, A., J. Bastin, K. Gould, G. Brownlee, A. Andrew, D. B. Boyle, Y. Chan, and G. L. Smith. 1988. Defective presentation to class-I restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigens. J. Exp. Med. 168:1211-1224.
46. Wesley, P. K., C. Clayberger, S. Lyu, and A. M. Krensky. 1993. The CD8 coreceptor interaction with the α3 domain of HLA class I is critical to the differentiation of human cytotoxic T lymphocytes specific for HLA-A2 and HLA-Cw4. Hum. Immunol. 36:149-155.
47. Witherspoon, R. P., L. D. Fisher, G. Schoch, P. Martin, K. M. Sullivan, J. Sanders, H. Deeg, K. Doney, D. Thomas, R. Storb, and E. D. Thomas. 1989. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N. Engl. J. Med. 321:784-789.
48. Zalani, S., E. Holley-Guthrie, and S. Kenney. 1996. Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell specific mechanism. Proc. Natl. Acad. Sci. USA 93:9194-9199.
49. Zemmour, J., and P. Parham. 1993. HLA class I nucleotide sequences, 1992. Immunogenetics 37:239-250.